Our new brochure on drug metabolites and C-H activated derivatives is now available. Inside we feature interesting case studies and client projects, including...
View Article
Our newsletter for Q4 2016 features case studies illustrating the creation of sulfated metabolites and, in some cases, co-production of other conjugates....
View Article
Hot-off-the-press news describing the scale-up of human metabolites resulting from mixed metabolism of Incyte’s first-in-class IDO1 inhibitor epacadostat (EPA) is...
View Article
Scientists at Lilly presented a poster at ISSX 2015 summarising results of an evaluation of Hypha’s drug metabolite screening panels. In it...
View Article
Dr Steve Wrigley will be talking at the forthcoming RSC conference “Bioactive Natural Products: Translating Promise into Practice” to be...
View Article
Our Business Development Manager, Frank Scheffler, will be presenting a poster at the Discovery Chemistry Congress in Berlin, Germany from...
View Article
Hypha produces acyl, N- and O-glucuronides of investigational new drugs at >90% purity and in yields typically between 5 and...
View Article
We are showcasing Hypha’s biotransformation capabilities at the ISSX meeting being held in San Francisco from 20th to 23rd October,...
View Article
We will be attending the RICT 2014 Interfacing Chemical Biology and Drug Discovery conference, being held in Rouen, France from 2nd-4th...
View Article
We are able to create mammalian metabolites of more complex structures as featured in our May 2014 newsletter, here using...
View Article
